Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Graft Versus Host Disease
Leukemia

First Posted Date: 2004-04-28

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004878

Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-23

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00005082

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00021008

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00021281

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Phase 2

Withdrawn

Conditions: Liver Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00020774

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-04-08

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00081042

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00081068

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 12 locations

SU006668 in Treating Patients With Advanced Solid Tumors

Phase 1

Conditions: Breast Cancer
Colorectal Cancer
Gastric Cancer
Kidney Cancer
Lung Cancer
Multiple Myeloma and Plasma Cell Neoplasm
Pancreatic Cancer
Prostate Cancer

First Posted Date: 2004-04-06

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00024063

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-05

Last Posted Date: 2013-09-20

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00023816

Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 4

Completed

Conditions: Anemia
Breast Cancer
Fatigue

First Posted Date: 2004-04-05

Last Posted Date: 2013-07-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00022386

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy